Cipla Limited
CIPLA
株式のランク
#1813
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
株価
$14.61
最終同期: 2026-10-19
時価総額
$11.81B
変化（1日）
-0.11%
変化（1年）
-21.65%
国
IN
取引 Cipla Limited (CIPLA)
カテゴリー
Healthcare
Cipla Limited（CIPLA）のP/E比率
October 2026 時点のP/E比率 TTM 31.89
Cipla Limited の最新の財務報告および株価によると、現在の P/E (TTM) は 31.89 です。2024 年末時点での P/E は 29.36 でした。
Cipla Limited の P/E 比率の履歴（2004 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 31.89 | 44.05% |
| 2025 | 22.14 | -24.59% |
| 2024 | 29.36 | 13.19% |
| 2023 | 25.94 | -20.52% |
| 2022 | 32.63 | 19.39% |
| 2021 | 27.33 | 24.01% |
| 2020 | 22.04 | -20.47% |
| 2019 | 27.71 | -15.71% |
| 2018 | 32.88 | -30.59% |
| 2017 | 47.37 | 56.68% |
| 2016 | 30.23 | -37.60% |
| 2015 | 48.45 | 118.85% |
| 2014 | 22.14 | 10.70% |
| 2013 | 20.00 | -6.60% |
| 2012 | 21.41 | -17.97% |
| 2011 | 26.10 | 5.68% |
| 2010 | 24.69 | 11.32% |
| 2009 | 22.18 | -9.06% |
| 2008 | 24.39 | -11.35% |
| 2007 | 27.52 | -15.81% |
| 2006 | 32.68 | 74.52% |
| 2005 | 18.73 | -18.42% |
| 2004 | 22.95 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | 9.62% |
IN
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。